TOPIC: Chest Infections TYPE: Medical Student/Resident Case Reports INTRODUCTION: Venous and arterial thrombi are both common complications seen in patients with COVID-19. This phenomenon may be due to the hyper-inflammatory state seen in COVID-19 infection. While venous thrombosis has been reported in 21% of patients with COVID-19, arterial thrombosis is more infrequent, reported in 2% of patients [1]. We present a patient with COVID-19 infection found to have pulmonary embolism (PE), left ventricular (LV) thrombus, and renal infarcts. CASE PRESENTATION: A 54-year-old male with a history of hypertension, diabetes mellitus, coronary artery disease, and heart failure with EF of 40% presented with worsening shortness of breath 10 days after having tested positive for SARS-COVID-19. The patient was placed on 100% FiO2 via high flow nasal cannula for acute hypoxic respiratory failure and started on dexamethasone, remdesivir, and enoxaparin for VTE prophylaxis.On day 6 of admission, the patient had acute onset pleuritic chest pain. ECG was unchanged from baseline and troponin level remained undetectable, however the d-dimer level increased from 338 ng/mL on admission to >10,000 ng/mL. CT chest with IV contrast revealed right upper lobe pulmonary emboli (Figure 1) and suspicion of left ventricular thrombus. The patient was started on therapeutic heparin infusion.TTE showed an akinetic left ventricular apex with echo density in apex suggestive of apical thrombus (Figure 2) and a 30% EF not seen previously. The patient was initiated on a heparin-warfarin bridge. On day 12 of admission, the patient experienced acute severe right lower quadrant pain. CT with IV contrast revealed multifocal large right renal infarcts with patent renal vessels (Figure 3). Because his renal function remained stable, no further intervention was taken. The patient's respiratory status began to improve and the patient was discharged home on warfarin. DISCUSSION: LV thrombus is a serious complication most often seen after acute myocardial infarction, but it can be found in 6% of patients with low ejection fraction and ischemic heart disease [2]. There have been reports of it in patients with COVID-19, particularly those with pre-existing cardiomyopathy such as our patient. LV thrombus would be unlikely to cause the PE seen in this patient, indicating the patient had unrelated venous and arterial thrombi due to COVID-19. However, the renal infarcts found after the patient had acute abdominal pain suggest that they are embolic from the LV thrombus. Early diagnosis and treatment of LV thrombus with warfarin as gold standard is important due to the high risk of stroke or systemic embolism [3]. CONCLUSIONS: There is an increased risk of both venous and arterial thrombi in COVID-19 despite prophylaxis. Patients with existing ischemic cardiomyopathy may be at risk for LV thrombus. Prompt recognition and management is critical to preventing additional venous and arterial embolic events and improving mortality. REFERENCE #1: Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020 Dec;29:100639. doi: 10.1016/j.eclinm.2020.100639. Epub 2020 Nov 20. REFERENCE #2: Aljaber NN, Mattash ZA, Alshoabi SA, Alhazmi FH. The prevalence of left ventricular thrombus among patients with low ejection fraction by trans-thoracic echocardiography. Pak J Med Sci. 2020 May-Jun;36(4):673-677. doi: 10.12669/pjms.36.4.1972. REFERENCE #3: Robinson AA, Trankle CR, Eubanks G, Schumann C, Thompson P, Wallace RL, Gottiparthi S, Ruth B, Kramer CM, Salerno M, Bilchick KC, Deen C, Kontos MC, Dent J. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi. JAMA Cardiol. 2020 Jun 1;5(6):685-692. doi: 10.1001/jamacardio.2020.0652. DISCLOSURES: No relevant relationships by Tony Li-Geng, source=Web Response no disclosure on file for Carrie Mahowald;